Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Sarcoma (Pediatric) Clinical Trials

A listing of Sarcoma (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (79) clinical trials

This goal of this study is to demonstrate a safe approach to increasing the activity of PD-1 immunotherapy in younger patients with solid tumors or lymphomas.  Eligible patients between the ages of 1 and 40 may receive repeating cycles of the PD-1 inhibitor, pembrolizumab, coupled with two therapies designed to ...

Phase

The purpose of the study is to evaluate the safety and tolerability of INCB059872 in participants with relapsed/refractory Ewing sarcoma.

Phase

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

PRIMARY OBJECTIVES: I. Assess the safety and tolerability of palbociclib when administered along with cisplatin or carboplatin. II. Establish the recommended phase 2 dose (RP2D) of the tested combinations. SECONDARY OBJECTIVES: I. Characterize the pharmacokinetic (PK) profiles of cisplatin, carboplatin. II. Obtain preliminary evidence of anti-tumor efficacy of the tested ...

Phase

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in ...

Phase

COM701 in Subjects With Advanced Solid Tumors

This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with a PD-1 inhibitor in subjects with advanced solid tumors. Cohort expansion will be explored evaluating COM701 monotherapy and ...

Phase

A Safety Study of SGN-CD47M in Patients With Solid Tumors

This is a dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of SGN-CD47M in adults with advanced solid tumors. The study will be conducted in 2 parts: Part A - Dose escalation: Up to approximately 25 patients will be treated to evaluate the safety, tolerability, ...

Phase

A Study Evaluating MM-310 in Patients With Solid Tumors

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a ...

Phase

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT organ SCT or for patients who ...

Phase

Pembrolizumab in Treating Younger Patients With Recurrent Progressive or Refractory High-Grade Gliomas Diffuse Intrinsic Pontine Gliomas Hypermutated Brain Tumors Ependymoma or Medulloblastoma

PRIMARY OBJECTIVES: I. To establish the safety and describe adverse effects associated with administration of the adult recommended dose of pembrolizumab (MK-3475) in each stratum separately. II. To estimate the sustained objective response rate, (complete response [CR] + partial response [PR], sustained for at least 9 weeks) associated with pembrolizumab ...

Phase

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and ...

Phase